XML 39 R29.htm IDEA: XBRL DOCUMENT v3.26.1
SEGMENT REPORTING (Tables)
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of research and development expenses
              
   Three Months Ended March 31, 
   2026   2025 
Personnel and consulting expenses  $1,209,211   $856,693 
External clinical study expenses   581,189    1,834,371 
Nonclinical and biomarker studies   538,077    92,401 
Chemistry Manufacturing & Control (“CMC”) related costs   236,767    436,854 
Total research and development expenses  $2,565,244   $3,220,319